RE:RE:RE:RE:RE:RE:Interim Data...Socks and blonds and other pumpers like sci fart may feel that ONE man show is better than a JV and that the market has valued the stock at less than 30 cents is the correct valuation for the company based on the clinical data so far. He or She or it or they may have their own their reasons that defies all Logic for simply extending all deadlines. Today's News report will prop the stock price for sometime till RDW decides on a next PP at 25 cents which will bring the market price down. Is this truly better than a JV and RDW losing control of the company to a JV partner who will ultimately be accountable to the share holders?